CDK4 and pancreatic ductal adenocarcinoma: It has been reported that MEK therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibition promotes a proangiogenic SASP in KRAS-mutant pancreatic ductal adenocarcinoma [25].